Dr. Jonathan A. Gutman, MD
Medical Oncology (Medical Oncology Physician)
12605 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 65
Licensed in Colorado since 2004, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CO license 43032 (first issued 2004; active) -
Hematology & Oncology Physician
CO license DR.0043032 (first issued 2004; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
- Uch-Memorial Health System Colorado Springs, CO
- Poudre Valley Hospital Fort Collins, CO
- Uchealth Broomfield Hospital Broomfield, CO
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 65
- Services billed
- 258
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 347 | 52 |
| Established patient office or other outpatient visit, 30-39 minutes | 86 | 32 |
| Hospital discharge day management, 30 minutes or less | 21 | 21 |
| Established patient office or other outpatient visit, 40-54 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Aurora, CO | 78 |
| Jakafi (ruxolitinib phosphate) | 53 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Aurora, CO | 25 |
| Rezurock (belumosudil mesylate) | 23 |
| Pantoprazole Sodium Other prescribers in Aurora, CO | 19 |
| Levothyroxine Sodium Other prescribers in Aurora, CO | 18 |
| Dexamethasone Other prescribers in Aurora, CO | 16 |
| Rosuvastatin Calcium Other prescribers in Aurora, CO | 12 |
| Tacrolimus Other prescribers in Aurora, CO | 11 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Aurora, CO | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 6 payments worth $15,960 in total to this clinician.
| Gamida Cell Inc. | $9,120 |
|---|---|
| National Marrow Donor Program | $5,000 |
| Melinta Therapeutics, LLC | $1,680 |
| Jazz Pharmaceuticals Inc. | $125 |
| AbbVie Inc. | $34.78 |
| Consulting Fee | $10,800 |
|---|---|
| Honoraria | $5,000 |
| Food and Beverage | $160 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gamida Cell Inc. Aug 21, 2025 | Consulting Fee OMISIRGE · ONCOLOGY | $9,120 |
| National Marrow Donor Program Jun 23, 2025 | Honoraria | $5,000 |
| Melinta Therapeutics, LLC Dec 16, 2025 | Consulting Fee Rezzayo · ANTIFUNGALS | $1,680 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $65,623 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT04161885 - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
Celgene Corporation - Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release
Celgene Corporation - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
E.r. Squibb & Sons, L.l.c. - M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. - Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
Janssen Research & Development, LLC - A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.